Biocad: all 94 studies

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)RecruitingNCT07742215Phase 3
• A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisRecruitingNCT07321093Phase 3
• Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus ErythematosusRecruitingNCT07136389Phase 1
• BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast CancerRecruitingNCT07108309Phase 2
• Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative ColitisRecruitingNCT07080034Phase 2
• Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's DiseaseRecruitingNCT07078994Phase 2
• Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy SubjectsRecruitingNCT06715540Phase 1
• An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia BRecruitingNCT06700096Phase 3
• An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple MyelomaRecruitingNCT06668792Phase 2
• A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple MyelomaRecruitingNCT06296121Phase 3
• Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)RecruitingNCT06120582Phase 1/2
• Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)RecruitingNCT05747261Phase 1/2
• Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®CompletedNCT04027803Phase 1Results posted
• The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy VolunteersCompletedNCT03693950Phase 1Results posted
• Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on DialysisCompletedNCT03519243Phase 2Results posted
• An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT03390101Phase 3Results posted
• First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy SubjectsCompletedNCT03103438Phase 1Results posted
• International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT02762994Phase 2Results posted
• Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®CompletedNCT02762799Phase 1Results posted
• Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy VolunteersCompletedNCT02731469Phase 1Results posted
• Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple SclerosisCompletedNCT02727907Phase 2/3Results posted
• Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy VolunteersCompletedNCT02506881Phase 1Results posted
• Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease PatientsCompletedNCT02506868Phase 3Results posted
• Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy VolunteersCompletedNCT02395055Phase 1Results posted
• First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy SubjectsCompletedNCT02380287Phase 1Results posted
• A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic SurgeriesCompletedNCT02368314Phase 3Results posted
• Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing SpondylitisCompletedNCT02359903Phase 1Results posted
• Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy VolunteersCompletedNCT02359877Phase 1Results posted
• Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer PatientsCompletedNCT02104830Phase 3Results posted
• An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected PatientsCompletedNCT02103439Phase 3Results posted
• Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy VolunteersCompletedNCT01766024Phase 1Results posted
• A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer PatientsCompletedNCT01764022Phase 3Results posted
• A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung CancerCompletedNCT01763645Phase 3Results posted
• Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis CCompletedNCT01740089Phase 2/3Results posted
• Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast CancerCompletedNCT01569087Phase 2Results posted
• A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy SubjectsCompletedNCT07181694Phase 1
• Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisActive, not recruitingNCT07119372Phase 3
• An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURNCompletedNCT06987864Phase 3
• An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCADCompletedNCT06987851Phase 3
• Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06640530Phase 3
• Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06640517Phase 3
• Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)Active, not recruitingNCT06333210Phase 3
• A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia AActive, not recruitingNCT06185335Phase 1/2
• A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06112808Phase 1
• Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3
• A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy SubjectsCompletedNCT05974969Phase 1
• Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerActive, not recruitingNCT05802225Phase 3
• A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid ArthritisActive, not recruitingNCT05800327Phase 3
• Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05783882Phase 3
• Phase 1 Study of BCD-245 in Subjects With NeuroblastomaStatus unknownNCT05782959Phase 1
• A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaActive, not recruitingNCT05751928Phase 3
• Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced MalignanciesActive, not recruitingNCT05739006Phase 1
• A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy VolunteersStatus unknownNCT05738993Phase 1
• A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaActive, not recruitingNCT05732805Phase 3
• Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)Active, not recruitingNCT05730699Phase 3
• Clinical Study of Divozilimab in Patients With Systemic SclerodermaActive, not recruitingNCT05726630Phase 3
• Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial SpondyloarthritisActive, not recruitingNCT05445076Phase 2
• Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy VolunteersCompletedNCT05407779Phase 1
• An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple SclerosisCompletedNCT05385744Phase 3
• Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)TerminatedNCT05037188Phase 1/2
• DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORsStatus unknownNCT04811443
• A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19CompletedNCT04397562Phase 3
• Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisCompletedNCT04227366Phase 3
• Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT04060264Phase 3
• Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple SclerosisCompletedNCT04056897Phase 2
• Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03913923Phase 2
• First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy SubjectsCompletedNCT03912441Phase 1
• Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)Status unknownNCT03912415Phase 3
• Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)Status unknownNCT03912402Phase 2
• Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLCStatus unknownNCT03912389Phase 3
• Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic ArthritisCompletedNCT03598751Phase 3
• Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT03551275Phase 1
• Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary CholangitisTerminatedNCT03476993Phase 2
• Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic MelanomaCompletedNCT03472027Phase 1
• A Study of BCD-135 in Patients With Advanced Solid TumorsStatus unknownNCT03464032Phase 1
• The BCD-089 (aIL6R) in Patients With Active Rheumatoid ArthritisCompletedNCT03455842Phase 2
• International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing SpondylitisCompletedNCT03447704Phase 3
• Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)Status unknownNCT03288870Phase 2/3
• International Trial of the Efficacy and Safety of BCD-100 in Patients With MelanomaStatus unknownNCT03269565Phase 2
• First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy SubjectsCompletedNCT03103451Phase 1
• Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast CancerCompletedNCT03065010Phase 1
• A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid TumorsStatus unknownNCT03050047Phase 1
• Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing SpondylitisCompletedNCT02763111Phase 2
• Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT02762955Phase 3
• Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisCompletedNCT02762838Phase 3
• Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing SpondylitisCompletedNCT02762812Phase 3
• Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT02753088Phase 3
• Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple SclerosisCompletedNCT02744222Phase 2/3
• Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid ArthritisCompletedNCT02744196Phase 3
• Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular DegenerationWithdrawnNCT02450981Phase 1
• Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular DegenerationWithdrawnNCT02036723Phase 3
• An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis CCompletedNCT01889433Phase 3
• Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid ArthritisCompletedNCT01759030Phase 3
• Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's LymphomaCompletedNCT01701232Phase 3

← Biocad overview and focus areas